These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 22661603)

  • 1. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
    Zhang H; Wroblewski K; Pu Y
    Acta Radiol; 2012 Jun; 53(5):561-8. PubMed ID: 22661603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
    Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
    Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
    J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy.
    Ikushima H; Dong L; Erasmus J; Allen P; McAleer MF; Zhuang Y; Sasaki R; Komaki R
    J Radiat Res; 2010; 51(4):465-71. PubMed ID: 20508373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
    Lin Y; Lin WY; Kao CH; Yen KY; Chen SW; Yeh JJ
    Anticancer Res; 2012 Nov; 32(11):5087-91. PubMed ID: 23155285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
    Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
    Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
    J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility study of FDG PET/CT-derived primary tumour glycolysis as a prognostic indicator of survival in patients with non-small-cell lung cancer.
    Mehta G; Chander A; Huang C; Kelly M; Fielding P
    Clin Radiol; 2014 Mar; 69(3):268-74. PubMed ID: 24315703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
    Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
    Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.